IDEXX Laboratories, Inc. (IDXX)- Traders Limelight

Friday, 13 Apr, 2018

Following the completion of the transaction, the director now directly owns 5,602 shares in the company, valued at approximately $1,064,716.12. Also, the number of active investment managers holding Idexx Laboratories Inc in their top 10 equity positions decreased from 12 to 11 for a decrease of 1. The stock price is showing encouraging image with current supportive move of 2.09% at trading price of $65.36. About 352,744 shares traded. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of IDEXX Laboratories by 1,000.0% during the fourth quarter. The stock outperformed the S&P500 by 12.44%.

Dt Investment Partners Llc increased its stake in Exelon Corp (EXC) by 14.16% based on its latest 2017Q4 regulatory filing with the SEC. Parnassus Investments bought 3,420 shares as the company's stock declined 6.32% with the market. The institutional investor held 66,090 shares of the health care company at the end of 2017Q4, valued at $10.34 million, up from 59,685 at the end of the previous reported quarter. The company has market cap of $8.28 billion.

IDEXX Laboratories, Inc. (IDXX) stock is now trading 11.20% away from its average-price of 200 days while it maintained a distance of -1.77% from its 50 Days Moving Average and -5.59% compared with the 20 Day Moving Average. The volume of 0.19 Million shares climbed down over an trading activity of 651.1 Million shares. It is down 0.00% since April 9, 2017 and is. It has underperformed by 4.21% the S&P500. BidaskClub cut shares of IDEXX Laboratories from a "hold" rating to a "sell" rating in a report on Saturday, December 16th.

Ratings analysis reveals 100% of Idexx Laboratories's analysts are positive. (NASDAQ:IDXX). Strategic Global Advsr Limited Company reported 0.52% of its portfolio in IDEXX Laboratories, Inc. Gulf Int Bank & Trust (Uk) has invested 0.06% in IDEXX Laboratories, Inc. (NASDAQ:IDXX) with "Buy" rating. The rating was upgraded by C.L. King to "Buy" on Friday, July 28. Canaccord Genuity maintained the shares of IDXX in report on Thursday, October 5 with "Buy" rating. The firm has "Buy" rating given on Monday, March 21 by Stifel Nicolaus.

NASDAQ IDXX opened at $192.41 on Thursday. Credit Suisse initiated the stock with "Outperform" rating in Thursday, February 4 report. The firm now has a "buy" rating on the stock. The company was maintained on Wednesday, April 13 by Credit Suisse. Canaccord Genuity's price objective would indicate a potential upside of 1.79% from the stock's previous close.

Now that you have a overview IDEXX Laboratories, Inc.'s performance, you can decided if it is worth pursuing further. 2,974 shares were sold by JUNIUS DANIEL M, worth $565,232 on Wednesday, February 28. 1,000 shares were bought by Kingsley Lawrence D, worth $178,045 on Wednesday, February 14. MCKEON BRIAN P sold $1.20 million worth of stock. On Thursday, February 22 the insider END WILLIAM T sold $737,939.

Honing in on some valuation rankings, IDEXX Laboratories, Inc. (NASDAQ:IDXX). Trust Of Vermont reported 0.01% stake. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.73 by $0.04. IDXX's profit would be $80.97 million giving it 51.95 P/E if the $0.93 EPS is correct. After $0.77 actual EPS reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts 20.78% EPS growth.

Investors sentiment decreased to 0.81 in Q4 2017. Its down 0.02, from 1.08 in 2017Q3. It fall, as 30 investors sold IDXX shares while 217 reduced holdings.

A number of hedge funds and other institutional investors have recently made changes to their positions in IDXX. 0 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data. State Board Of Administration Of Florida Retirement Sys owns 129,491 shares or 0.05% of their U.S. portfolio. (NASDAQ:FLXN). The Wisconsin-based 1492 Cap Mngmt Ltd Liability Corp has invested 0.47% in Flexion Therapeutics, Inc. (NASDAQ:IDXX). Raymond James & Assocs invested in 0.01% or 25,567 shares. Baystate Wealth Mngmt Limited Company holds 0.01% or 252 shares in its portfolio. Voya Inv holds 53,602 shares or 0.02% of its portfolio. Gsa Prtnrs Limited Liability Partnership holds 0.07% or 7,444 shares in its portfolio. Long Road Counsel Ltd reported 11,250 shares. (NASDAQ:FLXN). Jefferies Ltd Liability holds 0.01% of its portfolio in Flexion Therapeutics, Inc. Narrowing in a bit closer, the 5 month price index is 1.26112, the 3 month is 1.03165, and the 1 month is now 0.90808. (NasdaqGS:IDXX) is 26.342200. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. Mutual Of America Capital Management Lc owns 10,914 shares or 0.03% of their United States portfolio. (NYSE:CF). Canada Pension Plan Investment Board holds 0.01% or 138,114 shares. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock volatility for week was 2.95% while for month was 2.63%.Beta factor, which measures the riskiness of the security, was observed as 0.61. If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average - indicating a positive share price momentum. Praxair had 53 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has "Buy" rating by Canaccord Genuity given on Monday, August 21. Cowen & Co maintained the stock with "Hold" rating in Friday, May 5 report. The stock has "Equal-Weight" rating by Morgan Stanley on Tuesday, September 13. The company was maintained on Friday, February 2 by Bank of America.